Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery
暂无分享,去创建一个
Dion R. Brocks | D. Brocks | K. Wasan | Kristina Sachs-Barrable | Kishor M. Wasan | Stephen D. Lee | Sheila J. Thornton | K. Sachs-Barrable | Kristina Sachs-Barrable
[1] C. Porter,et al. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. , 1999, Journal of pharmaceutical sciences.
[2] N. Rifai,et al. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. , 1996, Clinical biochemistry.
[3] C. Porter,et al. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. , 1999, Journal of pharmaceutical sciences.
[4] M. Pessah,et al. Alterations of lecithin-cholesterol acyltransferase activity during Plasmodium chabaudi rodent malaria. , 1985, Biochimie.
[5] J. Wilschut,et al. Exchange of phosphatidylcholine between small unilamellar liposomes and human plasma high-density lipoprotein involves exclusively the phospholipid in the outer monolayer of the liposomal membrane. , 1983, Biochimica et biophysica acta.
[6] G. Gahrton,et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Breckenridge,et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.
[8] P. Mallon. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. , 2007, AIDS reviews.
[9] K. Wasan,et al. Cyclosporine Transfer from Low- and High-Density Lipoproteins Is Partially Influenced by Lipid Transfer Protein I Triglyceride Transfer Activity , 1999, Pharmaceutical Research.
[10] P. de Groen. Cyclosporine, low-density lipoprotein, and cholesterol. , 1988, Mayo Clinic proceedings.
[11] P. Nilsson-ehle,et al. Changes in plasma lipoproteins in acute malaria , 1990, Journal of internal medicine.
[12] R. Epand,et al. Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids. , 1986, The Journal of biological chemistry.
[13] M. Järvelin,et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. , 2005, The Journal of clinical psychiatry.
[14] K. Tsutsumi,et al. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. , 2001, Biological & pharmaceutical bulletin.
[15] G. Lopez-Berestein,et al. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. , 1990, International journal of obesity.
[16] R. Schiffelers,et al. Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. , 1997, Molecular pharmacology.
[17] R. Mahley,et al. Canine Lipoproteins and Atherosclerosis: I. Isolation and Characterization of Plasma Lipoproteins from Control Dogs , 1974, Circulation research.
[18] J D Terwilliger,et al. Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. , 1999, American journal of human genetics.
[19] P. Maurois,et al. [Changes of serum lipoproteins during the course of human malaria (author's transl)]. , 1980, Pathologie-biologie.
[20] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.
[21] I. Cockburn. Cyclosporine A: a clinical evaluation of drug interactions. , 1986, Transplantation proceedings.
[22] D. Kariuki,et al. EFFICACY OF MULTIPLE-DOSE HALOFANTRINE IN TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN CHILDREN IN KENYA , 1988, The Lancet.
[23] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[24] S. Grundy. Cholesterol and Atherosclerosis: Diagnosis and Treatment , 1990 .
[25] L. Benet,et al. Effects of low-density lipoprotein and ethinyl estradiol on cyclosporine metabolism in isolated rat liver perfusions. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[26] C. Fielding,et al. Mechanism of prebeta-HDL formation and activation. , 2006, Biochemistry.
[27] A. Radu,et al. The hyperlipidemic hamster as a model of experimental atherosclerosis. , 1987, Atherosclerosis.
[28] Moustapha Kassem,et al. Expression of LRP1 by Human Osteoblasts: A Mechanism for the Delivery of Lipoproteins and Vitamin K1 to Bone , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] Mi-Sook Kim,et al. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[30] T. V. van Berkel,et al. Synthesis of a Lipophilic Daunoruhicin Derivative and Its Incorporation into Lipidic Carriers Developed for LDL Receptor-Mediated Tumor Therapy , 1998, Pharmaceutical Research.
[31] W. Pardridge,et al. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. , 1979, Endocrinology.
[32] R. Morton,et al. Partial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma. , 2007, Atherosclerosis.
[33] W. Land,et al. Distribution and transfer of cyclosporine among the various human lipoprotein classes , 1983 .
[34] Ing-Kae Wang,et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules , 2007, Nature Structural &Molecular Biology.
[35] A. Garg,et al. Update on dyslipidemia. , 2007, The Journal of clinical endocrinology and metabolism.
[36] Miranda Beverly-Whittemore. The Effects of Light , 2005 .
[37] L. Lagrost,et al. Evidence for electronegativity of plasma high density lipoprotein-3 as one major determinant of human cholesteryl ester transfer protein activity. , 1996, Journal of lipid research.
[38] G. Lopez-Berestein,et al. Therapeutic Drug Monitoring of Cyclosporine‐Lipoprotein Levels , 1991, Pharmacotherapy.
[39] Valerie Taylor,et al. Associations between bipolar disorder and metabolic syndrome: A review. , 2006, The Journal of clinical psychiatry.
[40] R. Krauss,et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. , 1993, The Journal of clinical endocrinology and metabolism.
[41] G. Bray. The Zucker-fatty rat: a review. , 1977, Federation proceedings.
[42] G. Lopez-Berestein,et al. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins , 1993, Antimicrobial Agents and Chemotherapy.
[43] J. Wójcicki,et al. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. , 1985, Arzneimittel-Forschung.
[44] D. Marion,et al. Potential application of plant lipid transfer proteins for drug delivery. , 2001, Biochemical pharmacology.
[45] K. Wasan,et al. Effects of lipoproteins on cyclosporine A toxicity and uptake in LLC-PK1 pig kidney cells. , 2001, Journal of pharmaceutical sciences.
[46] F. Jamali,et al. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. , 1999, The Journal of pharmacology and experimental therapeutics.
[47] L. J. Brunner,et al. Effect of dietary oil intake on hepatic cytochrome P450 activity in the rat. , 2000, Journal of pharmaceutical sciences.
[48] K. Wasan,et al. Amphotericin B Lipid Complex or Amphotericin B Multiple-Dose Administration to Rabbits with Elevated Plasma Cholesterol Levels: Pharmacokinetics in Plasma and Blood, Plasma Lipoprotein Levels, Distribution in Tissues, and Renal Toxicities , 2001, Antimicrobial Agents and Chemotherapy.
[49] C Krogh,et al. "Compendium of pharmaceuticals and specialties". , 1983, Canadian Medical Association journal.
[50] F. Luft,et al. Megalin Deficiency Offers Protection from Renal Aminoglycoside Accumulation* , 2002, The Journal of Biological Chemistry.
[51] A. Tall. Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.
[52] C. Fielding,et al. Dynamics of lipoprotein transport in the human circulatory system , 2002 .
[53] E. Donnachie,et al. Effect of cyclosporine A on the binding affinity and internalization of low-density lipoproteins in human skin fibroblasts. , 2002, Journal of pharmaceutical sciences.
[54] L. Zucker. HEREDITARY OBESITY IN THE RAT ASSOCIATED WITH HYPERLIPEMIA * , 1965, Annals of the New York Academy of Sciences.
[55] R. Schwendener,et al. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-D-arabinofuranosylcytosine in Daudi lymphoma cells , 1999, British Journal of Cancer.
[56] M. Farquhar. The unfolding story of megalin (gp330): now recognized as a drug receptor. , 1995, The Journal of clinical investigation.
[57] B. Baas,et al. Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha. , 2001, Journal of pharmaceutical sciences.
[58] A. Tall,et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. , 1991, The Journal of biological chemistry.
[59] G. Forbes,et al. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. , 1987, The New England journal of medicine.
[60] D. Rossignol,et al. Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers , 2004, Antimicrobial Agents and Chemotherapy.
[61] G. Edwards,et al. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. , 1998, Journal of pharmaceutical sciences.
[62] T. Murakami,et al. Role of megalin in renal handling of aminoglycosides. , 2001, American journal of physiology. Renal physiology.
[63] D. Brocks,et al. The Influence of Hyperlipoproteinemia on in Vitro Distribution of Amiodarone and Desethylamiodarone in Human and Rat Plasma , 2007, Pharmaceutical Research.
[64] B. Iványi,et al. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts , 2006, Nature Clinical Practice Nephrology.
[65] I. Goldberg,et al. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[66] G. Forbes,et al. Central Nervous System Toxicity after Liver Transplantation , 1987 .
[67] K. Wasan,et al. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. , 1999, Journal of pharmaceutical sciences.
[68] W. Pardridge,et al. Influence of blood components on the tissue uptake indices of cyclosporin in rats. , 1988, The Journal of pharmacology and experimental therapeutics.
[69] A. Lacko,et al. High density lipoprotein complexes as delivery vehicles for anticancer drugs. , 2002, Anticancer research.
[70] Joachim Herz,et al. Apolipoprotein E receptors: linking brain development and alzheimer's disease , 2000, Nature Reviews Neuroscience.
[71] K. Wasan,et al. Lipid transfer protein I facilitated transfer of cyclosporine from low- to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity. , 1998, Journal of Pharmacology and Experimental Therapeutics.
[72] N. Maeda,et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[73] R. Maranhão,et al. Use of a cholesterol‐rich emulsion that binds to low‐density lipoprotein receptors as a vehicle for paclitaxel , 2002, The Journal of pharmacy and pharmacology.
[74] C. Porter,et al. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. , 1996, Journal of pharmaceutical sciences.
[75] E. Donnachie,et al. Differences in Lipoprotein Lipid Concentration and Composition Modify the Plasma Distribution of Cyclosporine , 1997, Pharmaceutical Research.
[76] P. May,et al. The LDL receptor‐related protein (LRP) family: An old family of proteins with new physiological functions , 2007, Annals of medicine.
[77] P. Linsel-Nitschke,et al. HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.
[78] Leslie Z. Benet,et al. High-Fat Meals Increase the Clearance of Cyclosporine , 2004, Pharmaceutical Research.
[79] B. Das,et al. Altered plasma lipid pattern in falciparum malaria. , 1992, Annals of tropical medicine and parasitology.
[80] R H Williams,et al. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. , 1992, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.
[81] C. T. Ueda,et al. Effects of Low and High Density Lipoproteins on Renal Cyclosporine A and Cyclosporine G Disposition in the Isolated Perfused Rat Kidney , 1997, Pharmaceutical Research.
[82] G. Dagenais,et al. Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[83] T. Johnston,et al. The poloxamer 407-induced hyperlipidemic atherogenic animal model. , 1997, Medicine and science in sports and exercise.
[84] V. Sulżyc-Bielicka,et al. Studies on the Pharmacokinetics and Pharmacodynamics of Propranolol in Hyperlipidemia , 1999, Journal of clinical pharmacology.
[85] K. Wasan,et al. Competitive Displacement of Clozapine from Plasma Proteins in Normolipidemic and Hyperlipidemic Plasma Samples: Clinical Implications , 2005, Drug development and industrial pharmacy.
[86] H. Arai,et al. Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. , 1993, The Journal of biological chemistry.
[87] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[88] J. Aberg,et al. Dyslipidemia in HIV patients. , 2005, Cleveland Clinic journal of medicine.
[89] T. Heath,et al. LDL Induced Association of Anionic Liposomes with Cells and Delivery of Contents as Shown by the Increase in Potency of Liposome Dependent Drugs , 2001, Pharmaceutical Research.
[90] Hyesung Jeon,et al. Structure and physiologic function of the low-density lipoprotein receptor. , 2005, Annual review of biochemistry.
[91] K. Wasan,et al. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. , 2004, Advanced drug delivery reviews.
[92] L. Bernstein,et al. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. , 2004, Journal of the National Cancer Institute.
[93] D. Brocks,et al. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat‐meal rat models , 2005, Biopharmaceutics & drug disposition.
[94] R. Schwendener,et al. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. , 1997, The Journal of pharmacology and experimental therapeutics.
[95] J. Barré,et al. Effects of Plasma Lipid Levels on Blood Distribution and Pharmacokinetics of Cyclosporin A , 1993, Therapeutic drug monitoring.
[96] K. Feingold,et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.
[97] L. Benet,et al. Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration , 1990, Journal of clinical pharmacology.
[98] K. Wasan,et al. Differences in Lipoprotein Concentration and Composition Modify the Plasma Distribution of Free and Liposomal Annamycin , 1996, Pharmaceutical Research.
[99] Y. Chao,et al. Hepatic catabolism of rat and human lipoproteins in rats treated with 17 alpha-ethinyl estradiol. , 1979, The Journal of biological chemistry.
[100] N. Ivankova,et al. Colorectal cancer and hypercholesterolemia: review of current research. , 2005, Experimental oncology.
[101] D. Brocks,et al. The Stereoselective Distribution of Halofantrine Enantiomers Within Human, Dog, and Rat Plasma Lipoproteins , 2000, Pharmaceutical Research.
[102] R. Sawchuk,et al. The pharmacokinetics of cyclosporine. II. Blood plasma distribution and binding studies. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[103] T. V. van Berkel,et al. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[104] L. Benet,et al. Transport and metabolism of cyclosporine in isolated rat hepatocytes. The effects of lipids. , 1992, Biochemical pharmacology.
[105] D. B. Zilversmit,et al. Cholesteryl ester exchange protein in human plasma isolation and characterization. , 1978, Biochimica et biophysica acta.
[106] A. Vinik. The metabolic basis of atherogenic dyslipidemia. , 2005, Clinical cornerstone.
[107] D. Vance,et al. Biochemistry of Lipids, Lipoproteins and Membranes , 2002 .
[108] R. Albrecht,et al. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr. , 2002, Journal of pharmaceutical sciences.
[109] A. Branchi,et al. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects , 2000, International journal of clinical & laboratory research.
[110] K. Wasan,et al. Plasma Lipoprotein Distribution of Liposomal Nystatin Is Influenced by Protein Content of High-Density Lipoproteins , 1998, Antimicrobial Agents and Chemotherapy.
[111] J. Vance. Assembly and secretion of lipoproteins , 2002 .
[112] M. C. Chang,et al. Induction of mid-term abortion by trichosanthin in laboratory animals. , 1979, Contraception.
[113] P. Shaw,et al. Trichosanthin interacts with and enters cells via LDL receptor family members. , 2000, Biochemical and biophysical research communications.
[114] David B. Evans,et al. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients , 1995, Clinical pharmacology and therapeutics.
[115] D. Pittet,et al. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. , 2003, The Lancet. Infectious diseases.
[116] D. Brocks,et al. Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function , 2006, The AAPS Journal.
[117] E. Barrett. Consensus development conference on antipsychotic drugs and obesity and diabetes. , 2004, Diabetes care.
[118] P. Moulin. Cholesteryl ester transfer protein: an enigmatic protein. , 1996, Hormone research.
[119] Han van de Waterbeemd,et al. Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..
[120] J. Bolard,et al. Antifungal agents useful in therapy of systemic fungal infections. , 1983, Annual review of pharmacology and toxicology.
[121] T. Ishida,et al. A Mutant High-Density Lipoprotein Receptor Inhibits Proliferation of Human Breast Cancer Cells , 2004, Cancer Research.
[122] D. Brocks,et al. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat , 2006, Biopharmaceutics & drug disposition.
[123] R. D. Meyer,et al. Current role of therapy with amphotericin B. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[124] Hughes Ta,et al. Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. , 1991 .
[125] J. Racoosin,et al. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.
[126] B. Kasiske,et al. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. , 1992, Hypertension.
[127] T. Kooistra,et al. Mouse models for atherosclerosis and pharmaceutical modifiers. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[128] S. Chueh,et al. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1 , 2003, Transplantation.
[129] A. Young,et al. Rapid cycling bipolar disorder: historical overview and focus on emerging treatments. , 2004, Bipolar disorders.
[130] J. Keyser,et al. Cyclosporin leukoencephalopathy induced by intravenous lipid solution , 1992, The Lancet.
[131] N. Baquer,et al. Adaptive responses of enzymes of carbohydrate and lipid metabolism to dietary alteration in genetically obese Zucker rats (fa/fa). , 1978, European journal of biochemistry.
[132] M. Brown,et al. Lipoprotein receptors and the genetic control of cholesterol metabolism in cultured human cells , 1975, Naturwissenschaften.
[133] D. Brocks,et al. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. , 2002, Journal of pharmaceutical sciences.
[134] J. Newcomer,et al. Medical risk in patients with bipolar disorder and schizophrenia. , 2006, The Journal of clinical psychiatry.
[135] H. Lodish,et al. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. , 1994, The Journal of biological chemistry.
[136] J. Goldstein,et al. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts , 1975, Cell.
[137] T. V. van Berkel,et al. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. , 1998, British Journal of Cancer.
[138] K. Wasan,et al. Cyclosporine A transfer between high- and low-density lipoproteins: independent from lipid transfer protein I-facilitated transfer of lipoprotein-coated phospholipids because of high affinity of cyclosporine a for the protein component of lipoproteins. , 2001, Journal of pharmaceutical sciences.
[139] M. Droździk,et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects , 2003, Biopharmaceutics & drug disposition.
[140] K. Wasan,et al. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. , 1998, Journal of pharmaceutical sciences.
[141] M. Oda,et al. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B Published, JLR Papers in Press, November 28, 2005. , 2006, Journal of Lipid Research.
[142] M. Kazemi,et al. Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma , 1997, Antimicrobial agents and chemotherapy.
[143] F. Meunier. Alternative modalities of administering amphotericin B: current issues. , 1994, The Journal of infection.
[144] K. Wasan,et al. Plasma protein and lipoprotein distribution of clozapine. , 2001, The American journal of psychiatry.
[145] S. Moestrup,et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. , 1995, The Journal of clinical investigation.
[146] G. Friedman,et al. Drug-related dyslipidemia after renal transplantation. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[147] J. Montaner,et al. Adverse effects of antiretroviral therapy for HIV infection. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[148] F. Alvarez,et al. Long-term problems related to immunosuppression. , 2006, Transplant immunology.
[149] T. Willnow,et al. Lipoprotein receptors: new roles for ancient proteins , 1999, Nature Cell Biology.
[150] K. Wasan,et al. Acute P-407 Administration to Mice Causes Hypercholesterolemia by Inducing Cholesterolgenesis and Down-Regulating Low-Density Lipoprotein Receptor Expression , 2006, Pharmaceutical Research.
[151] P. Brouqui,et al. Hypertriglyceridemia as an indicator of the severity of falciparum malaria in returned travelers: a clinical retrospective study , 2004, Parasitology Research.
[152] T. Heath,et al. LDL-induced association of anionic liposomes with cells and delivery of contents. II. Interaction of liposomes with cells in serum-containing medium. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[153] F. Jamali,et al. Effects of Hyperlipidemia on the Pharmacokinetics of Nifedipine in the Rat , 1999, Pharmaceutical Research.
[154] T. Willnow,et al. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? , 2002, Trends in cell biology.
[155] A. Lakkaraju,et al. Low-density Lipoprotein Receptor-related Protein Mediates the Endocytosis of Anionic Liposomes in Neurons* 210 , 2002, The Journal of Biological Chemistry.
[156] S. Marder,et al. Novel antipsychotics: comparison of weight gain liabilities. , 1999, The Journal of clinical psychiatry.
[157] C. Fielding,et al. Isolation and characterization of a human serum cholesteryl ester transfer protein. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[158] P. C. Groen. Cyclosporine, low-density lipoprotein, and cholesterol. , 1988 .
[159] D. Sgoutas,et al. Interaction of cyclosporin A with human lipoproteins * , 1986, The Journal of pharmacy and pharmacology.
[160] D. Strickland,et al. LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.
[161] K. Vadiei,et al. Cyclosporine disposition in the hyperlipidemic rat model. , 1988, Research communications in chemical pathology and pharmacology.
[162] R. Pease,et al. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine , 1987, Cell.
[163] P. Günzel,et al. Serum Lipoprotein Pattern in Rats, Dogs and Monkeys, Including Method Comparison and Influence of Menstrual Cycle in Monkeys , 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[164] G. Gahrton,et al. HYPOCHOLESTEROLAEMIA IN MALIGNANCY DUE TO ELEVATED LOW-DENSITY-LIPOPROTEIN-RECEPTOR ACTIVITY IN TUMOUR CELLS: EVIDENCE FROM STUDIES IN PATIENTS WITH LEUKAEMIA , 1985, The Lancet.
[165] D. Cutler,et al. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2007 .
[166] W. El-Sadr,et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral‐naïve cohort , 2005, HIV medicine.
[167] P. Gambert,et al. Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI* , 2005, Journal of Biological Chemistry.
[168] N. Maeda,et al. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[169] G. Lopez-Berestein,et al. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.
[170] M. Camilo,et al. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. , 2001, Clinical nutrition.
[171] H. Deeg,et al. HIGH CYCLOSPORIN LEVELS AFTER BONE MARROW TRANSPLANTATION ASSOCIATED WITH HYPERTRIGLYCERIDAEMIA , 1986, The Lancet.
[172] G. Lopez-Berestein,et al. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion , 1994, Antimicrobial Agents and Chemotherapy.
[173] D. Wirshing. Schizophrenia and obesity: impact of antipsychotic medications. , 2004, The Journal of clinical psychiatry.
[174] U. Cavallaro,et al. Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. , 1995, European journal of biochemistry.
[175] M. Farquhar,et al. Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[176] D. Rader. Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.
[177] K. Oka,et al. Serum cholesterol levels and kidney transplantation outcome: attenuation of cyclosporine efficacy? , 2001, Transplantation.
[178] T. Sakaeda,et al. Effect of serum triglyceride concentration on the fluctuation of whole blood concentration of cyclosporin A in patients. , 2001, Biological & pharmaceutical bulletin.
[179] J. Barwicz,et al. A kinetic study of the oxidation effects of amphotericin B on human low‐density lipoproteins , 2000, FEBS letters.
[180] R. Hammer,et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.
[181] R. Sawchuk,et al. Effect of co‐administration of intralipidTM on the pharmacokinetics of cyclosporine in the rabbit , 1991, Biopharmaceutics & drug disposition.
[182] M. Brown,et al. Role of the low density lipoprotein receptor in regulating the content of free and esterified cholesterol in human fibroblasts. , 1975, The Journal of clinical investigation.
[183] C. Porter,et al. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.
[184] H. Webster,et al. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. , 1988, Bulletin of the World Health Organization.
[185] B. Carter,et al. Effects of Pravastatin on Plasma Lipid Concentrations in Poloxamer 407‐Induced Hyperlipidemic Rats , 1995, Pharmacotherapy.
[186] T. Johnston,et al. Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. , 1999, Journal of cardiovascular pharmacology.
[187] M. Bateson,et al. GALACTORRHŒA WITH CIMETIDINE , 1977, The Lancet.
[188] B. Karten,et al. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. , 2000, The Biochemical journal.
[189] G. Lopez-Berestein,et al. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. , 1994, Journal of pharmaceutical sciences.
[190] D. Rader,et al. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. , 2006, Circulation.
[191] H. Schmid,et al. Hypertriglyceridemia as a possible risk factor for prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.
[192] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[193] A. Tall,et al. Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. , 1983, The Journal of biological chemistry.